Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593773 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT02593773 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 86 participants.
The verdict
NCT02593773, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this phase 3 multi-center, open-label extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia.
Interventions
- DRUG Interferon γ-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-12-25 |
| Est. Completion | 2017-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593773
The ClinicalTrials.gov registry entry for NCT02593773 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon γ-1b is the first listed.
NCT02593773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593773 about?
NCT02593773 is a clinical study titled "Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study". The purpose of this phase 3 multi-center, open-label extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia.
What is the current status of trial NCT02593773?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2015-12-25. Estimated completion is 2017-03-21.
What interventions are being tested in trial NCT02593773?
The interventions under investigation include: Interferon γ-1b (DRUG).
Who is sponsoring clinical trial NCT02593773?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.